Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):: US8256933024
LEI:
Country:: United States of America
Address:: 401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Website:: https://shuttlepharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Carisma Therapeutics Inc. Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.	United States of America	CARM
Cartesian Therapeutics, Inc. Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.	United States of America	RNAC
CASI Pharmaceuticals, Inc. Develops and commercializes drugs for oncology, transplant, and autoimmune disease.	United States of America	CASI
CASSAVA SCIENCES INC Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.	United States of America	SAVA
CATALYST PHARMACEUTICALS, INC. Advancing therapies for rare neuromuscular and neurological diseases like LEMS.	United States of America	CPRX
cbdMD, Inc. Produces & distributes lab-tested CBD wellness products for people and pets.	United States of America	YCBD
CDT Equity Inc. Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.	United States of America	CDT
CELADON PHARMACEUTICALS PLC Vertically integrated pharma developing cannabis medicines for chronic pain.	United Kingdom	CEL
Celcuity Inc. Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.	United States of America	CELC
Celemics, Inc. Develops custom NGS panels and bioinformatics for research and clinical diagnostics.	South Korea	331920